PERTZYE

Phase 2Biologic

AbbVie

PERTZYE is one of 113 biologic programs targeting Liver Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Cystic FibrosisActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Cystic FibrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Onglyza

AstraZeneca

Preclinical

2 2

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 3

PERTZYE

AbbVie

Phase 2

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 9

Capromorelin

UUniversity of Aarhus

Preclinical

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT05642962

Q1 2028

Phase 2Not yet recruiting

Liver Transplant

NCT07335523

Clinical

Trials by Indication[1]

Cystic Fibrosis1 trial

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Terminated· AbbVie logo

AbbVie··NCT01652157·17 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05642962·17 enrolled

Liver Transplant1 trial

Management of Steatorrhea in Children and Young Adults With Alagille Syndrome After Liver Transplantation

Not yet recruiting·DDigestive Care, Inc.·Phase 2·NCT07335523·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PERTZYE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PERTZYE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PERTZYE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AbbVie

PERTZYE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Cystic Fibrosis1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Liver Transplant1 trial

References

Drug Info

Quick Facts

Related News